The Serological Sciences Network (SeroNet); the U.S. government’s effort to boost testing capacity and escalate standardized research on immune responses to SARS-CoV-2

Abstract In April 2020, the National Cancer Institute (NCI) and Frederick Laboratory for Research (FNLCR) built Serological Sciences Network(SeroNet) on foundation of HPV Serology program to develop serology technologies better understand immune response infection vaccines. SeroNet members (steering committee, investigators, working groups) are funded by NCI (through The Paycheck Protection Program Healthcare Enhancement Act) characterize responses elicited SARS-CoV-2 modifiers mechanisms driving these responses, serological correlates disease pathogenesis/protection, barriers testing. Studies were conducted 8 Centers Excellence 13 Projects, with reference material development longitudinal vaccine studies at FNLCR 4 subcontracted Capacity Building (CBCs). CBC testing capacity has reached >5,000 tests/week collected >8000 aliquots serum/peripheral blood mononuclear cells (PBMC) samples ~3000 healthy control/immunocompromised patients (serum, PBMC’s, clinical/follow up data) use SeroNet. produced 332 papers protection characterization response. Study level data 87 is found in Immunology Database Analysis Portal (ImmPort). study design templates, standard operating procedures, common elements, well-characterized standards, such as first US standard, which calibrated against WHO International Standard evaluation panels facility assay validation.